| Home | E-Submission | Sitemap | Editorial Office |  
top_img
   
ORIGINAL ARTICLE 2022 August 16
Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis
Purpose We intend to investigate the oncological efficacy and feasibility of local consolidative therapy (LCT) through a meta-analysis method. Materials and Methods Four databases including PubMed, MEDLINE, Embase, and Cochrane library were searched. Target studies are controll...
ORIGINAL ARTICLE 2022 January 17
Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
Purpose This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF) or bronchial washing fluid (BWF), and pleural effusi...
ORIGINAL ARTICLE 2021 November 19
The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non–Small Cell Lung Cancer
Purpose The illness-death model (IDM) is a comprehensive approach to evaluate the relationship between relapse and death. This study aimed to illustrate the value of the IDM for identifying risk factors and evaluating predictive probabilities for relapse and death in patients wi...
Current Issue
Volume 54(4); Oct 2022
Volume 54(3); July 2022
Volume 54(2); April 2022
RSS feed
Editorial
951 Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment
Dae Ho Lee
Cancer Res Treat. 2022;54(4):951-952.   Published online October 4, 2022    DOI: https://doi.org/10.4143/crt.2022.1326
                              
Original Articles
General
953 Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis
Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Eui Kyu Chie, Yong Chan Ahn, The Oligometastasis Working Group, Korea Cancer Association
Cancer Res Treat. 2022;54(4):953-969.   Published online August 16, 2022    DOI: https://doi.org/10.4143/crt.2022.329
                              Supplementary         Cited By 1
970 Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study
Anikó Bozsik, János Papp, Vince Kornél Grolmusz, Attila Patócs, Edit Oláh, Henriett Butz
Cancer Res Treat. 2022;54(4):970-984.   Published online February 8, 2022    DOI: https://doi.org/10.4143/crt.2021.1078
                              Supplementary      
Lung and Thoracic cancer
985 Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
Yeon Joo Kim, Won Jun Ji, Jae-Cheol Lee, Sung-Min Chun, Chang-Min Choi
Cancer Res Treat. 2022;54(4):985-995.   Published online January 17, 2022    DOI: https://doi.org/10.4143/crt.2021.857
                              Supplementary      
996 The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non–Small Cell Lung Cancer
Kum Ju Chae, Hyemi Choi, Won Gi Jeong, Jinheum Kim
Cancer Res Treat. 2022;54(4):996-1004.   Published online November 19, 2021    DOI: https://doi.org/10.4143/crt.2021.902
                              Supplementary      
1005 A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
Cancer Res Treat. 2022;54(4):1005-1016.   Published online December 3, 2021    DOI: https://doi.org/10.4143/crt.2021.986
                              Supplementary         Cited By 1
1017 The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
Xiaoyan Sun, Yingnan Feng, Bin Zhang, Wuhao Huang, Xiaoliang Zhao, Hua Zhang, Dongsheng Yue, Changli Wang
Cancer Res Treat. 2022;54(4):1017-1029.   Published online November 23, 2021    DOI: https://doi.org/10.4143/crt.2021.1007
                                 Cited By 1
1030 Long-term Exposure to PM10 Increases Lung Cancer Risks: A Cohort Analysis
Hyun Woo Lee, Sung-Chan Kang, Sun-Young Kim, Young-Jae Cho, Seungsik Hwang
Cancer Res Treat. 2022;54(4):1030-1037.   Published online January 17, 2022    DOI: https://doi.org/10.4143/crt.2021.1030
                              Supplementary         Cited By 1
Breast cancer
1038 Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study
Wei Ren, Yunfang Yu, Huangming Hong, Ying Wang, Quanlong Gao, Yongjian Chen, Peixian Chen, Jianli Zhao, Qiyun Ou, Dagui Lin, Tuping Fu, Yujie Tan, Chenchen Li, Xinxin Xie, Guolin Ye, Jun Tang, Herui Yao
Cancer Res Treat. 2022;54(4):1038-1052.   Published online February 4, 2022    DOI: https://doi.org/10.4143/crt.2021.698
                              Supplementary         Cited By 1
1053 Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
Helen P. Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, Anna Batistatou, Kyriaki Papadopoulou, Mattheos Bobos, Anthoula Asimaki-Vlachopoulou, Sofia Chrisafi, Kitty Pavlakis, Kyriakos Chatzopoulos, Eleni Galani, George Pentheroudakis, Dimitrios Pectasides, Dimitrios Bafaloukos, Eleni Res, Pavlos Papakostas, Angelos Koutras, Vassiliki Kotoula, George Fountzilas
Cancer Res Treat. 2022;54(4):1053-1064.   Published online November 17, 2021    DOI: https://doi.org/10.4143/crt.2021.748
                              Supplementary      
1065 Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors
Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Na Yeon Kim, Sungkeun Shim, Ho Young Kim, Danbee Kang, Juhee Cho, Eunsook Lee, Yoon Jung Chang, Hyunsoon Cho
Cancer Res Treat. 2022;54(4):1065-1073.   Published online December 8, 2021    DOI: https://doi.org/10.4143/crt.2021.835
                              Supplementary         Cited By 1
1074 Lobular Carcinoma In Situ during Preoperative Biopsy and the Rate of Upgrade
Jeea Lee, Ga Yoon Ku, Haemin Lee, Hyung Seok Park, Ja Seung Ku, Jee Ye Kim, Seho Park, Byeong-Woo Park
Cancer Res Treat. 2022;54(4):1074-1080.   Published online December 21, 2021    DOI: https://doi.org/10.4143/crt.2021.864
                              
1081 Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer
Kyung-Hwak Yoon, Yeshong Park, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Se Hyun Kim, Koung Jin Suh, Sun Mi Kim, Mijung Jang, Bo La Yun, So Yeon Park, Hee-Chul Shin
Cancer Res Treat. 2022;54(4):1081-1090.   Published online November 17, 2021    DOI: https://doi.org/10.4143/crt.2021.890
                              
1091 Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
Ji-Yeon Kim, Seok Jin Nam, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Jin Seok Ahn, Young-Hyuck Im, Seok Won Kim, Yeon Hee Park
Cancer Res Treat. 2022;54(4):1091-1098.   Published online January 10, 2022    DOI: https://doi.org/10.4143/crt.2021.901
                              Supplementary         Cited By 1
1099 Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer
Ji Soo Park, Saeam Shin, Yoon Jung Lee, Seung-Tae Lee, Eun Ji Nam, Jung Woo Han, Sun Hwa Lee, Tae Il Kim, Hyung Seok Park
Cancer Res Treat. 2022;54(4):1099-1110.   Published online November 17, 2021    DOI: https://doi.org/10.4143/crt.2021.978
                              Supplementary      
1111 The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer
In Hye Song, Young-Ae Kim, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, Yeon ho Choi, Heejae Lee, Jeong-Han Seo, Youngjin Cho, Sung Wook Jung, Hee Jeong Kim, Sei Hyun Ahn, Hee Jin Lee, Gyungyub Gong
Cancer Res Treat. 2022;54(4):1111-1120.   Published online December 21, 2021    DOI: https://doi.org/10.4143/crt.2021.1017
                              Supplementary      
1121 The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim
Cancer Res Treat. 2022;54(4):1121-1129.   Published online December 31, 2021    DOI: https://doi.org/10.4143/crt.2021.1083
                              Supplementary      
1130 Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Yong-Pyo Lee, Min-Sang Lee, HongSik Kim, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2022;54(4):1130-1137.   Published online January 17, 2022    DOI: https://doi.org/10.4143/crt.2021.1103
                              Supplementary         Cited By 1
Gastrointestinal cancer
1138 Prevalence of Psychological Symptoms in Patients Undergoing Pancreatoduodenectomy and Results of a Distress Management System: A Clinic-Based Study
Mee Joo Kang, Eun-Seung Yu, Young Hwa Kang, Hyeong Min Park, Sang-Jae Park, Sun-Whe Kim, Jong-Heun Kim, Sung-Sik Han
Cancer Res Treat. 2022;54(4):1138-1147.   Published online January 4, 2022    DOI: https://doi.org/10.4143/crt.2021.842
                              Supplementary      
1148 Role of Esophagectomy after Chemoradiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma: A Comparative Analysis Stratified by Clinical Response to Chemoradiation Therapy
Jesang Yu, Jong Hoon Kim, Sung-Bae Kim, Sook Ryun Park, Young-Hee Kim, Hyeong Ryul Kim, Hyun Joo Lee, Ho June Song, Kye Jin Song, Jeong Yun Jang, Yoon Young Jo, Ye Jin Yoo
Cancer Res Treat. 2022;54(4):1148-1156.   Published online December 20, 2021    DOI: https://doi.org/10.4143/crt.2021.885
                              Supplementary      
1157 Aberrant DNA Methylation Maker for Predicting Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasms
Cheol Min Shin, Nayoung Kim, Hyuk Yoon, Yoon Jin Choi, Ji Hyun Park, Young Soo Park, Dong Ho Lee
Cancer Res Treat. 2022;54(4):1157-1166.   Published online January 18, 2022    DOI: https://doi.org/10.4143/crt.2021.997
                              Supplementary      
1167 Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
Sora Kang, Min-Hee Ryu, Yeong Hak Bang, Hyung-Don Kim, Hyung Eun Lee, Yoon-Koo Kang
Cancer Res Treat. 2022;54(4):1167-1174.   Published online December 6, 2011    DOI: https://doi.org/10.4143/crt.2021.1040
                              Supplementary         Cited By 3
1175 Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer
Jaewon Hyung, Eun Jeong Cho, Jihun Kim, Jwa Hoon Kim, Jeong Eun Kim, Yong Sang Hong, Tae Won Kim, Chang Ohk Sung, Sun Young Kim
Cancer Res Treat. 2022;54(4):1175-1190.   Published online January 12, 2022    DOI: https://doi.org/10.4143/crt.2021.1133
                              Supplementary         Cited By 1
Genitourinary cancer
1191 Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho
Cancer Res Treat. 2022;54(4):1191-1199.   Published online December 7, 2021    DOI: https://doi.org/10.4143/crt.2021.985
                              Supplementary      
Gynecologic cancer
1200 Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers
Joseph J. Noh, Min Kyu Kim, Min Chul Choi, Jeong-Won Lee, Hyun Park, Sang Geun Jung, Won Duk Joo, Seung Hun Song, Chan Lee
Cancer Res Treat. 2022;54(4):1200-1208.   Published online December 13, 2021    DOI: https://doi.org/10.4143/crt.2021.828
                              Supplementary         Cited By 1
1209 Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation
Yuchun Wei, Chuqing Wei, Liang Chen, Ning Liu, Qiuxiang Ou, Jiani C. Yin, Jiaohui Pang, Zhenhao Fang, Xue Wu, Xiaonan Wang, Dianbin Mu, Yang Shao, Jinming Yu, Shuanghu Yuan
Cancer Res Treat. 2022;54(4):1209-1218.   Published online January 17, 2022    DOI: https://doi.org/10.4143/crt.2021.963
                              Supplementary      
1219 Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy
Aeran Seol, Ga Won Yim, Joo Yeon Chung, Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong Sang Song
Cancer Res Treat. 2022;54(4):1219-1229.   Published online November 17, 2021    DOI: https://doi.org/10.4143/crt.2021.1010
                              Supplementary      
Pediatric cancer
1230 Outcome of Intensive Therapy for Children with Relapsed Acute Myeloid Leukemia: A Single Institution Korean Study
Jae Wook Lee, Jae Won Yoo, Seongkoo Kim, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho
Cancer Res Treat. 2022;54(4):1230-1239.   Published online December 17, 2021    DOI: https://doi.org/10.4143/crt.2021.1011
                              Supplementary      
Sarcoma
1240 Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study
Joonha Kwon, Jun Hyeong Lee, Young Han Lee, Jeeyun Lee, Jin-Hee Ahn, Se Hyun Kim, Seung Hyun Kim, Tae Il Kim, Kum-Hee Yun, Young Suk Park, Jeong Eun Kim, Kyu Sang Lee, Jung Kyoon Choi, Hyo Song Kim
Cancer Res Treat. 2022;54(4):1240-1255.   Published online January 17, 2022    DOI: https://doi.org/10.4143/crt.2021.1194
                              Supplementary         Cited By 2
Hematologic malignancy
1256 Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
Do Young Kim, Jehyun Nam, Joo-Seop Chung, Byeol Eun Jeon, Ji Hyun Lee, Jae-Cheol Jo, Sang-Woo Kim, Ho-Jin Shin
Cancer Res Treat. 2022;54(4):1256-1267.   Published online December 31, 2021    DOI: https://doi.org/10.4143/crt.2021.944
                              Supplementary      
1268 Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2022;54(4):1268-1277.   Published online December 30, 2021    DOI: https://doi.org/10.4143/crt.2021.1168
                              Supplementary      
1278 Tables of Contents (Vol. 54, No. 1~4, 2022)
Cancer Res Treat. 2022;54(4):1278-1288.
      
1289 Acknowledgment of Reviewers (2022)
Cancer Res Treat. 2022;54(4):1289-1292.
      
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Impact factor
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI